Sinova

Quick links to important sections

Sinova

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinova

What is Sinova? (Simvastatin)

Sinova is a prescription medication used for systemic lipid regulation, primarily by lowering abnormally elevated fats in the bloodstream. It belongs to the HMG-CoA reductase inhibitor class of drugs, commonly known as statins.

Property Description
Active ingredient Simvastatin (an inactive lactone prodrug)
Form Tablet or Film-coated tablet (oral administration)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
General purpose Lowering LDL-C (Bad Cholesterol)
Origin Semi-synthetic (derived from a fungal fermentation product)

What Type of Medicine is Sinova (Simvastatin)?

Sinova is an orally administered medication containing the single active ingredient, Simvastatin, which is supplied primarily in a tablet or film-coated tablet form. Its primary classification is as an HMG-CoA reductase inhibitor, a designation commonly referred to as a statin, reflecting its established role in controlling blood lipids. Simvastatin is chemically categorized as a semi-synthetic derivative, meaning its structure is based on a natural fungal compound that has been subsequently modified.

A unique differentiating factor is that Simvastatin functions as a prodrug; it is an inactive molecule upon ingestion and must be metabolized by the liver into its active \beta-hydroxy acid form to produce its therapeutic effect. This mechanism is clinically recognized for providing effective modulation of endogenous cholesterol production.

What is the General Purpose of Sinova?

The general purpose of Sinova is to provide systemic lipid regulation by acting as a lipid-lowering agent. This core function is accomplished through the drug's mechanism of inhibiting the enzyme necessary for the body's internal synthesis of cholesterol in the liver.

By modulating this vital metabolic pathway, Sinova is effective at reducing the concentration of circulating low-density lipoprotein cholesterol (LDL-C), frequently termed "bad" cholesterol. Statins play an essential role in reducing the risk of heart problems in patients at high risk of coronary events. The final benefit of the medicine is to manage this major risk factor, thereby supporting overall cardiovascular health, which represents its typical, non-specific therapeutic use.

Regulatory References

  1. NIH/StatPearls, Simvastatin Therapy
  2. EMA Simvastatin Referral

What side effects are possible with Sinova?

Possible Side Effects and Safety Information

The official safety profile for Sinova (Simvastatin) outlines adverse reactions based on frequency and affected body system, strictly according to regulatory classifications from government authorities. While many documented effects are Common, specific Rare and Very Rare events are highlighted due to their clinical significance.


Adverse Reaction Scope

Category Documented Effects (Examples)
Common Upper respiratory infection, headache, constipation, abdominal pain, nausea.
Rare Myopathy (muscle pain/weakness), rhabdomyolysis, hepatitis, pancreatitis, peripheral neuropathy.
Very Rare Fatal and non-fatal hepatic failure, anaphylaxis, muscle rupture.
System Classes Musculoskeletal and Connective Tissue, Hepatobiliary, Nervous System, Gastrointestinal.

Serious Safety Concerns and Restrictions

Serious Adverse Reactions: The most critical safety elements documented in regulatory labels relate to muscle and liver function, specifically Myopathy and Rhabdomyolysis (severe muscle breakdown). Rhabdomyolysis is a rare but life-threatening event. Reports of fatal and non-fatal Hepatic Failure are also classified as Very Rare serious adverse events.

Population-Specific Safety: Advanced age (ge 65 years) and severe renal impairment are listed in official labeling as risk factors for myopathy. The medication is formally contraindicated by regulatory agencies in individuals with active liver disease, during pregnancy, and during lactation.

Exposure Patterns: The risk of myopathy is noted to be disproportionately increased at the 80 mg dose, particularly during the first twelve months of treatment. Certain drug combinations or the consumption of large amounts of grapefruit juice are also documented as increasing the risk of myopathy and rhabdomyolysis.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents regarding Simvastatin overdosage provide specific guidance on emergency actions and anticipated outcomes. It is mandated that individuals seek immediate medical attention following any suspected overdosage.

Documented Overdose Manifestations

The regulatory labeling notes that in reported cases of acute Simvastatin overdosage, including instances where individuals ingested up to 3.6 g, all patients recovered without lasting ill effects, known as sequelae. Consequently, there are no specific acute symptoms or physiological manifestations explicitly documented in the official Overdosage section of the drug's prescribing information.

Emergency Management and Procedural Notes

Management for overdosage consists primarily of general symptomatic and supportive measures. There is no specific antidote documented in the regulatory information for Simvastatin. Furthermore, the official guidance explicitly notes that due to the drug’s high degree of binding to plasma proteins, procedures such as hemodialysis are not expected to be beneficial as a supportive treatment. Medical monitoring remains required to assess the patient's clinical status following ingestion.

Therapeutic Uses of Sinova

Key Uses and Benefits of Sinova

Sinova is commonly used for managing conditions associated with acute or disruptive symptom patterns, offering short-term symptomatic assistance to help patients cope with heightened distress.

The medication is applicable in clinical settings marked by increased discomfort or tension, providing supportive relief when symptoms interfere with routine activities. Its use is generally considered relevant for easing the overall symptom load when symptoms cluster into patterns. This approach aligns with clinical practices for managing symptomatic episodes.

The primary therapeutic areas of use include managing episodic discomfort, supporting patients through functional strain, and addressing acute symptom clusters. By helping to ease distress, Sinova supports patients during difficult episodes, which may help maintain a sense of stability and improve comfort during symptomatic periods.

“It provides support that helps ease the overall burden of symptoms during periods when they become more noticeable.”


Quick Fact: Assisting with Episodic Discomfort

Sinova may be part of symptomatic management when symptoms related to heightened physiological activity and systemic imbalance become temporarily overwhelming. It assists with maintaining functional stability when symptoms escalate temporarily.

Eligibility and Restrictions for Use

The eligibility for using Sinova (Simvastatin) is defined by official regulatory documents based on patient population, health status, and age.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed: Adults with primary hyperlipidemia; Adolescents (aged 10–17) with Heterozygous Familial Hypercholesterolemia (HeFH) who have failed diet therapy.
Populations for whom use is contraindicated: Patients with active liver disease (including unexplained persistent elevation of liver enzymes); those with known hypersensitivity to Simvastatin; and those requiring concomitant use of strong CYP3A4 inhibitors (e.g., specific antifungals, certain antibiotics).
Age-related eligibility rules: Use is restricted to patients aged 10 years and older. Use in children younger than 10 years has not been established. Advanced age (ge 65 years) is documented as a predisposing factor for myopathy.
Pregnancy and lactation eligibility status: Use is contraindicated in pregnant women due to the potential for fetal harm. The medicine is not recommended for women who are breastfeeding.

Eligibility-Related Restrictions

The 80 mg dosage is restricted only to patients who have been taking that dose for 12 months or more without muscle toxicity; it must not be started in new patients. Use requires caution in patients with severe renal impairment, uncontrolled hypothyroidism, or a history of hereditary muscular disorders.


Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the medicine by establishing clear contraindications (e.g., active liver disease, pregnancy) that prohibit use, and by applying restrictions based on age thresholds, concomitant medication use, and underlying conditions like severe renal impairment, thereby structuring the appropriate patient population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sinova (Simvastatin) is a prodrug that is a substrate for the metabolic enzyme Cytochrome P450 3A4 (CYP3A4) and the hepatic uptake transporter OATP1B1. Interactions with other substances are primarily pharmacokinetic, leading to elevated plasma concentrations of the active drug and a formally documented increase in the risk of serious muscle disorders, including myopathy and rhabdomyolysis.

Certain combinations are strictly contraindicated due to this elevated risk. Co-administration of Sinova is prohibited with strong CYP3A4 inhibitors (such as specific antifungals, macrolide antibiotics, and HIV protease inhibitors), as well as with Cyclosporine, Danazol, and Gemfibrozil.

Drug Interactions Requiring Dose Restrictions

Increased Simvastatin exposure from co-administered agents requires specific maximum daily dose restrictions as documented in regulatory labels:

Interacting Agent Classification Sinova Maximum Daily Dose Restriction
Verapamil, Diltiazem, Dronedarone Do not exceed 10 mg daily.
Amiodarone, Amlodipine, Ranolazine, Lomitapide Do not exceed 20 mg daily.

Food and Pharmacodynamic Interactions

Consumption of large quantities of grapefruit juice (more than one quart daily) is advised to be avoided due to its CYP3A4 inhibitory effect. The combined use of Sinova with other fibrates or lipid-modifying doses of Niacin (≥ 1 g/day) poses an additive risk of myopathy. Furthermore, co-administration with coumarin anticoagulants (e.g., Warfarin) is documented to prolong the International Normalized Ratio (INR).

Mechanism of Action

The mechanism of Simvastatin (Sinova) operates across two critical and sequential domains within hepatic lipid metabolism, resulting in the modulation of circulating cholesterol concentration. The process involves modulation of the liver's internal regulatory systems.

1. Competitive Inhibition of Cholesterol Biosynthesis

The drug, which is initially an inactive prodrug, is activated in the liver into its beta-hydroxy acid form. This active metabolite competitively inhibits the enzyme HMG-CoA Reductase, which is the rate-limiting step in the Mevalonate pathway. By blocking this key enzyme, the drug suppresses the liver's ability to manufacture cholesterol internally. This initial molecular action creates an intentional deficit of cholesterol within the liver cells, which acts as the crucial trigger for the subsequent compensatory response.

2. Enhanced Systemic Clearance via Receptor Upregulation

The resulting low internal cholesterol level activates a homeostatic feedback mechanism, leading the liver cells (hepatocytes) to upregulate the synthesis and surface density of Low-Density Lipoprotein (LDL) receptors. These newly expressed receptors actively bind to and efficiently remove LDL-C and related lipoprotein particles directly from the bloodstream. This enhancement of plasma clearance is the final physiological consequence of the drug's mechanism, resulting in an adjustment in systemic lipid concentration.

Dosage and Administration Information

How Sinova is Used: Official Administration Guidelines

Sinova (Simvastatin) is a prescription medicine administered for systemic lipid regulation. Its administration is based on specific guidelines governing the route, timing, dose ranges, and necessary adjustments for safe, long-term use.


Administration Scope

Instruction Detail
Route of administration The medication is taken orally as a tablet.
Frequency and timing Sinova is taken once daily and must be administered in the evening to align with the body’s natural rhythm of cholesterol production.
Timing in relation to meals Administration is independent of food and can be taken with or without food.
Preparation requirements The tablet must be swallowed whole with water and should not be crushed, cut, or chewed.
Special procedural conditions Dose adjustment is mandatory when taken concurrently with certain interacting medicines, as detailed in the official product information.

Official Dosing and Adjustment

The standard approach to Sinova use involves starting with a low dose, which is then gradually adjusted. The typical initial dose ranges from 10 mg to 20 mg once daily. The maintenance dose range is generally between 5 mg and 40 mg, with 40 mg being the current standard maximum daily dose for most patients. Doses are typically titrated (adjusted) upward at intervals of four weeks or longer to achieve the desired therapeutic effect. For individuals with severe renal impairment (kidney problems), the dose should not exceed 10 mg daily unless used under strict medical guidance.

This structured approach ensures the medication is introduced and maintained according to the official long-term use protocol, strictly defining how the dose is initiated and adjusted over time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sinova (Simvastatin)

This overview describes the research landscape for Sinova (Simvastatin) based on reports from regulatory agencies and peer-reviewed scientific literature, focusing on the types of studies conducted, the outcomes they tracked, and what remains to be fully characterized.


Evidence for Patients with Established Heart Disease (Secondary Prevention)

Research into the use of Sinova for secondary prevention—that is, for patients who have already experienced a major cardiovascular event—primarily relies on large-scale Randomized Controlled Trials (RCTs). These pivotal studies, such as the Scandinavian Simvastatin Survival Study (4S) and the Heart Protection Study (HPS), was studied for comparison against a control over several years.

The main outcomes monitored in these trials were designed to track long-term clinical patterns, including the rate of future Major Cardiovascular Events (MACE) such as non-fatal heart attacks or strokes, and overall All-Cause Mortality. Research from these foundational studies describes the patterns of cardiovascular event rates observed in the study populations. These patterns have been further explored in large systematic reviews and meta-analyses.


Evidence for Patients with High Risk but No Event History (Primary Prevention)

The evidence supporting the use of Sinova in primary prevention also stems from large Randomized Controlled Trials and subsequent meta-analyses. These trials focused on research examining the difference in the rate of a first major event between the treatment group and the control group over defined time intervals. Research has also examined the relationship between the measured change in lipid biomarkers, such as Low-Density Lipoprotein Cholesterol (LDL-C), and the patterns of cardiovascular outcomes that were observed during the study periods, which contributes to the broader evidence landscape of lipid management.


Research Gaps and Remaining Uncertainties

While the evidence base is extensive, data for very low-risk populations remain insufficient to fully characterize potential long-term outcomes. Furthermore, regulatory reviews note that comparative evidence regarding the clinical outcomes of Sinova at standard doses versus the highest doses of other statins was observed in indirect comparisons or meta-analyses, and direct head-to-head evidence remains limited. The long-term context of continuous use beyond the trial period is not fully established by existing long-term trial data. Research provides context but not individual predictions.

Key Studies & References

  1. MRC/BHF Heart Protection Study (HPS): A randomised placebo-controlled trial in 20,536 high-risk individuals.
  2. NICE Guideline NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification.

Frequently Asked Questions (FAQ)

Common questions about Sinova (FAQ)


Q: How quickly do people typically expect to notice an effect from Sinova?

The therapeutic effect of Sinova is assessed by monitoring Low-Density Lipoprotein Cholesterol (LDL-C) levels in the blood. Regulatory administration guidelines describe that dosage adjustments, known as titration, are typically performed at intervals of four weeks or longer. This period allows observation of the patient's lipid response before a maintenance dose is determined.


Q: Can Sinova be taken long-term, or is it only for short-term use?

Treatment for systemic lipid regulation with this class of medicine is generally intended for a long duration. Official prescribing information describes protocols that govern the long-term use of this medication. The cardiovascular benefits achieved through lipid management are usually sustained only for as long as the medication is taken.


Q: Is it normal to feel [vague side effect like tiredness] after starting Sinova?

Tiredness or unusual weakness is a symptom that has been reported in association with the use of Sinova. Official safety information highlights that unusual fatigue or muscle weakness may be signs of more serious, rare side effects, such as myopathy (muscle pain/weakness). Concerns about persistent or concerning fatigue should be discussed with a healthcare professional.


Q: Do the side effects of Sinova usually go away over time?

Official clinical information indicates that most documented adverse effects are generally mild and may resolve on their own, or after a dosage adjustment is made. If a serious or concerning adverse event occurs, discontinuation of the medication is a possible option to resolve the issue. The regulatory review of the drug's safety profile considers the benefits against the risk of these adverse reactions.


Q: What kinds of non-prescription products or supplements might interact with Sinova?

Official documents specifically warn against consuming large quantities of grapefruit juice (more than one quart daily) while using Sinova. The combined use with fibrates or lipid-modifying doses of Niacin (ge 1 g/day) is associated with a greater risk of muscle problems. Regulatory warnings for interactions are primarily focused on substances that affect the enzyme CYP3A4.


Q: Is Sinova a controlled substance or habit-forming?

Sinova (Simvastatin) is categorized as a prescription-only medication used for systemic lipid regulation. Official classifications confirm that this medicine is not designated as a controlled substance and is not considered habit-forming.


Q: Is it true that Sinova requires special monitoring like blood tests?

According to official prescribing information, monitoring is required before and periodically during treatment with Sinova. Specifically, liver enzyme levels need to be checked through blood tests. Additionally, blood work to assess cholesterol levels is necessary to determine the therapeutic response to the medication.


Q: What happens if I accidentally miss a dose of Sinova?

Official patient information provides general guidance if a dose of Sinova is missed. Regulatory documents state that if the missed dose is remembered later the same day, it may be taken. However, if it is not remembered until the following day, the regulatory advice is generally to skip the dose and resume the normal dosing schedule. It is advised never to take two doses to make up for a missed one.


Q: Why do some people report feeling [vague emotional effect] when they take Sinova?

Official safety updates for the statin class of medicines, including Simvastatin, have included post-marketing reports of neurological and emotional effects. These reports include instances of memory loss, sleep disturbances (like insomnia and nightmares), and depression. However, official documents often note that the actual frequency of these reported effects is not precisely known or cannot be reliably estimated from the data.


Q: Does Sinova affect fertility in men or women?

Official documentation does not contain clear evidence indicating that Simvastatin reduces fertility in men or women. However, Sinova is formally contraindicated in pregnant women due to the potential for fetal harm. Because of this contraindication, healthcare providers usually recommend that the medicine be stopped if a person becomes pregnant or is planning to conceive.


Q: Are there official warnings about operating machinery while on Sinova?

Official patient information states that Sinova is generally not expected to impair the ability to drive or operate machinery. However, as with many medications, some individuals may experience dizziness. Individuals should monitor their reaction to the medication before engaging in activities that require full attention.


Q: Can elderly patients generally use Sinova safely?

Official regulatory documents permit the use of Sinova in elderly patients. However, advanced age (65 years and older) is listed as a predisposing factor for muscle-related serious adverse events, such as myopathy. Due to this increased risk profile, the need for closer monitoring should be discussed with a healthcare professional.


Q: How does Sinova affect sleep patterns?

Official drug safety profiles for the statin class of medications, including Sinova, have documented reports of sleep pattern changes. Specifically, adverse events such as insomnia and nightmares have been associated with the use of the medicine.


Q: Are the pills of Sinova available in different shapes or colors?

Simvastatin, the active ingredient in Sinova, is available in multiple tablet strengths from various manufacturers. Because of this, the pills may indeed vary in shape, color, and imprints depending on the specific company and dose. Confirmation of the tablet's physical description against the information provided by the dispensing pharmacy is recommended.


Q: How long does Sinova stay in your system after you stop taking it?

Sinova is chemically recognized as a shorter-acting statin, which is consistent with the official instruction to take it in the evening. Pharmacokinetic studies describe that the active metabolite of the drug has a short half-life. This means the substance is metabolized and cleared from the body relatively quickly after administration.


Q: Does taking Sinova require any lifestyle changes, like quitting smoking?

Official information indicates the medication is prescribed as part of a comprehensive management program that often includes supportive measures. This often involves components like a low-fat, low-cholesterol diet and incorporating physical activity, in line with overall cardiovascular health guidance.


Q: What is the risk of an allergic reaction to Sinova?

A known hypersensitivity (severe allergic response) to Simvastatin is formally listed as a contraindication. Regulatory documents note that severe allergic reactions, such as anaphylaxis and significant facial swelling, are documented as very rare adverse events.


Q: Is Sinova available as a generic version?

Yes, Sinova is the brand name for the active ingredient Simvastatin. Simvastatin is widely available from many pharmaceutical companies as a generic alternative.


Q: Do official documents mention any potential for long-term side effects from Sinova?

Official regulatory documents list all known adverse reactions, which include rare and very rare events like myopathy or hepatic failure, regardless of when they may occur during use. These lists cover potential effects that have been reported from clinical trials and long-term post-marketing surveillance. However, official evidence notes that the long-term context of continuous use beyond the initial trial period has not been fully established.


Q: What are the most common reasons why doctors might discontinue Sinova for a patient?

According to official prescribing information, treatment with Sinova should be immediately discontinued if the patient develops signs of muscle problems, such as myopathy, or if blood tests indicate liver damage. These two serious concerns are the primary stated reasons in regulatory documents for immediate cessation of the drug during therapy.


Q: Does Sinova contain any common allergens like gluten or lactose?

The official formulations of Simvastatin tablets from many manufacturers commonly include the sugar lactose as an inactive ingredient. Regulatory summaries for some brands have explicitly stated that they do not contain gluten or tartrazine.


Q: Is Sinova the kind of medicine that can cause a 'rebound effect' if stopped suddenly?

Official patient information indicates that withdrawal symptoms are generally not an expected reaction when Sinova is stopped suddenly. However, stopping the drug is likely to cause cholesterol levels to return to their previous elevated state. This rise in lipid levels can potentially increase the risk of cardiovascular problems over time.


Q: Does Sinova affect blood sugar levels?

Regulatory safety communications indicate that the statin class of medicines, including Sinova, is associated with an observed small increased risk of developing Type 2 diabetes. This association is related to an observed increase in blood sugar levels.


Q: Can I take pain relievers while I am on Sinova?

Official drug labels prioritize reporting interactions with specific medication classes, such as strong CYP3A4 inhibitors and certain heart medicines. Common over-the-counter pain relievers, such as ibuprofen or acetaminophen, are generally not listed in formal regulatory documentation as agents that require dose adjustment or are strictly contraindicated.


Q: Why does the Sinova package insert mention specific patient populations?

The package insert details specific patient populations, such as adolescents, the elderly, or those with severe renal impairment, because these groups have unique considerations. Official guidance includes special dosing recommendations, formal contraindications, or known risk factors for adverse events like myopathy that apply distinctly to these populations.


Q: What are the main points of confusion about taking Sinova with or without food?

The most important clarification from official administration instructions is that the Sinova tablets can be taken with or without food. The primary timing requirement is that the dose must be taken once daily and administered in the evening to align with the body's cholesterol production rhythm.


Q: What does 'use with caution' mean in the official Sinova documents?

The official phrase 'use with caution' is a regulatory designation indicating that the medicine is generally allowed but is associated with a heightened risk in the specified population (e.g., those with severe renal impairment). When this designation is applied, it means that the patient requires continuous and close monitoring by a healthcare professional during therapy.

How should Sinova be stored and disposed of?

How to Store and Dispose of Sinova (Simvastatin)

Official labeling defines specific conditions for storing Sinova tablets to maintain stability and effectiveness.

Storage Requirements

Sinova must be stored at Controlled Room Temperature, defined as between 20 C and 25 C (68 F and 77 F). The medication must be protected from moisture and high heat.

Storage Condition Requirement
Temperature Controlled Room Temperature
Container Store in original, tightly closed container
Environment Protect from moisture and high heat
Safety Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Sinova must not be flushed down the toilet or placed in household wastewater. The preferred method for discarding the product is by taking it to a local drug take-back program or a community collection point for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinova found in:

A-Z Index: